Novavax, Inc. (NasdaqGS:NVAX) plans on raising $200 million the proceeds of which will be used for the advancement of its clinical-stage vaccine candidates, including its recently initiated pivotal Phase 3 clinical trials of its RSV F Vaccine in older adults and pregnant women, as well as its other clinical and preclinical research programs, and general corporate purposes, which may include working capital, product development, manufacturing and process development expenditures, capital expenditures, acquisitions and other strategic purposes. The offering was upsized to $300 million from the previously announced size of $200 million.